Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 2OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Lymphoma 17Leukemia, Myeloid, Acute 16Breast Neoplasms 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Multiple Myeloma 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma, Non-Hodgkin 11Carcinoma, Non-Small-Cell Lung 11Lymphoma, Mantle-Cell 10Leukemia 10Lymphoma, Follicular 9Hodgkin Disease 9Myelodysplastic Syndromes 8Recurrence 7Neuroblastoma 7Neoplasm Metastasis 7Leukemia, Lymphocytic, Chronic, B-Cell 7Brain Neoplasms 7Neoplasms, Plasma Cell 6Lymphoma, B-Cell, Marginal Zone 6Lung Neoplasms 6Glioblastoma 6Prostatic Neoplasms 5Pancreatic Neoplasms 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, T-Cell 5Lymphoma, Large-Cell, Anaplastic 5Lymphoma, B-Cell 5Immunoblastic Lymphadenopathy 5Burkitt Lymphoma 5

Interventions

Docetaxel 11Cisplatin 11Biopsy 7Radiotherapy 6Immunohistochemistry 6Carboplatin 6pembrolizumab 5Radiotherapy, Intensity-Modulated 5Magnetic Resonance Spectroscopy 5Cetuximab 5Trastuzumab 4Paclitaxel 4Nivolumab 4Gemcitabine 4Chemotherapy, Adjuvant 4Capecitabine 4Surgical Procedures, Operative 3Specimen Handling 3Radiosurgery 3Ipilimumab 3Goserelin 3Fluorodeoxyglucose F18 3Everolimus 3Erlotinib Hydrochloride 3sacituzumab govitecan 2pyrotinib 2pertuzumab 2bicalutamide 2Taxes 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Salivary Gland Neoplasms × Vorinostat × Clear all
NCT02538510 2024-11-26

Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

University of Washington

Phase 1/2 Completed
50 enrolled 13 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡